Low dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: a randomized 4-way crossover trial with nasal cavity dimension assessment by Quintana, Daniel et al.
OPEN
ORIGINAL ARTICLE
Low-dose oxytocin delivered intranasally with Breath Powered
device affects social-cognitive behavior: a randomized four-
way crossover trial with nasal cavity dimension assessment
DS Quintana1, LT Westlye1,2, ØG Rustan1, N Tesli1, CL Poppy1,2, H Smevik1,2, M Tesli1, M Røine3, RA Mahmoud4, KT Smerud3,
PG Djupesland5 and OA Andreassen1
Despite the promise of intranasal oxytocin (OT) for modulating social behavior, recent work has provided mixed results. This may
relate to suboptimal drug deposition achieved with conventional nasal sprays, inter-individual differences in nasal physiology and a
poor understanding of how intranasal OT is delivered to the brain in humans. Delivering OT using a novel ‘Breath Powered’ nasal
device previously shown to enhance deposition in intranasal sites targeted for nose-to-brain transport, we evaluated dose-
dependent effects on social cognition, compared response with intravenous (IV) administration of OT, and assessed nasal cavity
dimensions using acoustic rhinometry. We adopted a randomized, double-blind, double-dummy, crossover design, with 16 healthy
male adults completing four single-dose treatments (intranasal 8 IU (international units) or 24 IU OT, 1 IU OT IV and placebo). The
primary outcome was social cognition measured by emotional ratings of facial images. Secondary outcomes included the
pharmacokinetics of OT, vasopressin and cortisol in blood and the association between nasal cavity dimensions and emotional
ratings. Despite the fact that all the treatments produced similar plasma OT increases compared with placebo, there was a main
effect of treatment on anger ratings of emotionally ambiguous faces. Pairwise comparisons revealed decreased ratings after 8 IU OT
in comparison to both placebo and 24 IU OT. In addition, there was an inverse relationship between nasal valve dimensions and
anger ratings of ambiguous faces after 8-IU OT treatment. These ﬁndings provide support for a direct nose-to-brain effect,
independent of blood absorption, of low-dose OT delivered from a Breath Powered device.
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INTRODUCTION
A growing body of evidence demonstrates a critical role of
oxytocin (OT) in social cognition and behavior.1–3 For instance, a
single administration of OT increases empathy,4,5 trust,6 group-
serving behaviors,7,8 sensitivity of eye gaze9 and theory-of-mind
performance in healthy individuals10 and in patients with
psychiatric disorders.11 Due to this burgeoning literature, OT has
been proposed as a novel therapy for disorders characterized by
social dysfunction, such as autism and schizophrenia spectrum
disorders.12,13 In spite of initial promise, however, recent work
has either failed to identify changes in social behavior after
OT administration14 or has provided results that are only
signiﬁcant in speciﬁc subgroups or contexts.15 Although these
mixed results have been largely attributed to such contextual and
individual differences,16 factors that may inﬂuence biological
activity of intranasal exogenous OT—such as dose, nasal cavity
dimensions and delivery method—have yet to be thoroughly
investigated.15,17,18
The two-level model of OT response highlights the important
role of targeted intranasal delivery and nasal physiology in
intranasal OT administration, describing three pathways to the
central nervous system (CNS) from the nose.18 Intranasally
administered OT can enter the CNS indirectly via mechanisms
such as capillary uptake in the nasal vasculature with subsequent
penetration of the blood–brain barrier (BBB) in the walls of the
cerebral capillaries or through the more leaky barrier between the
blood and the cerebrospinal ﬂuid in the choroid plexus (that is,
blood-to-cerebrospinal ﬂuid barrier).15,17,19–21 However, only very
small—but perhaps still biologically signiﬁcant19—amounts of OT
enter the CNS via these indirect routes.22 Alternatively, perineural
bulk transport along ensheathed channels surrounding the
olfactory and trigeminal nerve ﬁber pathways offer two rapid
and direct routes from the nasal cavity to the CNS, circumventing
the BBB.15,18,23 Olfactory nerve ﬁbers innervate a limited segment
of the deep upper narrow nasal passage, while the trigeminal
nerve provides sensory and parasympathetic innervation to the
deep upper and posterior segments of the nasal cavity. To reach
these crucial targets for nose-to-brain delivery, intranasally
administered OT needs to initially overcome, among other
challenges, the problem of delivery to areas beyond the nasal
valve.15 This valve region is a narrow triangular-shaped opening
located 2–3 cm from the nostrils.24 Given the barrier that this
dynamic structure presents, it is unsurprising that traditional nasal
delivery devices deposit mainly in or anterior to this narrow valve
with a minimal fraction going on to reach the upper posterior
segments housing the key nose-to-brain target sites.25–27 Nasal
valve dimensions vary between individuals and over time, and are
1NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, University of Oslo, Oslo, Norway; 2Department of
Psychology, University of Oslo, Oslo, Norway; 3Smerud Medical Research International AS, Oslo, Norway; 4OptiNose US Inc, Yardley, PA, USA and 5OptiNose AS, Oslo, Norway.
Correspondence: Professor OA Andreassen, NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, University of
Oslo, Building 49, Ullevål, Kirkeveien 166, PO Box 4956 Nydalen, N-0424 Oslo, Norway.
E-mail: o.a.andreassen@medisin.uio.no
Received 2 June 2015; accepted 2 June 2015
Citation: Transl Psychiatry (2015) 5, e602; doi:10.1038/tp.2015.93
www.nature.com/tp
dependent on multiple factors, including overall health,28 septal
deviation,29 mucosal inﬂammation and nasal polyps.30 However,
despite the important role of the nasal valve in intranasal drug
administration it has yet to be considered in the context of OT
delivery. Nasal valve dimensions could provide a measurable
parameter that could further inform the role of delivery
mechanism and deposition pattern on treatment efﬁcacy.
Improvement of intranasal delivery of OT to target sites beyond
the nasal valve may yield improved pharmacodynamic (PD)
effects. The recent development of Breath Powered closed-palate
Bi-Directional technology (Supplementary Figure S1; OptiNose,
Oslo, Norway) creates an opportunity to investigate a new form of
intranasal delivery that is hypothesized, by virtue of direct nose-to-
brain activity, to produce PD effects in the brain disproportionate
to what would be achieved by absorption into the blood and
transport across the BBB into the brain. It is reasonable to surmise
that this type of targeted delivery may improve the reliability,
therapeutic index and magnitude of OT treatment effects due to
improved drug deposition;15,31,32 however, no prior research has
investigated the PD response to OT delivered using this device.
Though generally accepted, the assumption that nasal delivery is
an effective way of delivering OT to modulate social cognition and
behavior has not been experimentally scrutinized in humans.15
Early work demonstrated that intravenous (IV) administration can
inﬂuence social behavior and cognition33,34—presumably via blood
absorption and subsequent action across the BBB—however, all
subsequent human studies assessing the effect of OT on cognitive
functions have used methods that deliver OT via the nasal cavity.
Although there is a strong theoretical basis that intranasal delivery
is a more appropriate means of administering OT to the CNS given
increases in cerebrospinal ﬂuid concentrations of OT after intranasal
administration,35 a controlled comparison of PD effects after
intranasal (that is, nose-to-brain) and IV (that is, transportation
across the BBB) administration is of interest.18 Greater central effects
(for example, social cognition) after targeted intranasal drug
delivery, in the presence of comparable blood exposure, would
provide much-needed support for direct nose-to-brain activity.
Another hurdle for the development of OT as a therapeutic
intervention is the deﬁnition of an optimal dosing regimen. The
majority of intranasal OT studies evaluated between 20 and 40
international units (IU).36 However, there is no comprehensive
empirical evidence substantiating this dosage, despite calls for
such research18,37,38 and successful efforts in other disciplines (for
example, obstetrics39). The negative long-term effects of OT
treatment observed in non-human adolescent mammals,40 and
the presence of OT and cross-reactive vasopressin (AVP) receptors
throughout the body41 that are involved in a variety of
homeostatic functions related to observed side effects,42 further
reinforces the axiomatic importance of identifying the lowest
effective doses of OT.
To date, no controlled clinical trial has investigated the effect of
different intranasal OT dosages vs IV OT on social cognition or the
role of nasal dimensions in OT treatment response. This
randomized, double-blind, double-dummy, four-way crossover
trial in healthy volunteers compared PD outcome on social
cognition, as indexed by performance on a computerized
emotional faces rating paradigm, between four treatments: ‘low
dose’ (8 IU) OT delivered with the Breath Powered OptiNose
device (OPN-OT), ‘higher dose’ (24 IU) OPN-OT, OT delivered
intravenously (IV OT; 1 IU) and placebo. Although the comparison
of OT administration with a traditional hand-actuated spray pump
is of theoretical interest, this would require the inclusion of
additional OT and placebo arms and an especially complex
double-dummy design for appropriate double-blinding (that is,
successive administration of solution with the OPN-OT device and
hand-actuated device, with associated concerns regarding a
‘washout’ effect). Moreover, doubling the delivered volume from
300 μl per nostril would by far exceed the recommended
maximum volume and increase drug drip-out and swallowing.
Primary outcomes were the evaluation of facial emotional
expression and secondary outcomes including pharmacokinetic
proﬁles and ratings of trustworthiness. First, we hypothesized a
main effect of OPN-OT on the perceived intensity of anger, given
neural,43 behavioral44–47 and anxiolytic48 evidence for the role of
OT in processing social threat stimuli, and that this effect would be
more pronounced with ambiguous emotional stimuli compared
with stimuli with less ambiguous emotional expressions in light of
prior research43 and the general ambiguity of social signals.48
Although OT appears to inﬂuence the processing of negative
social stimuli in general, this effect may be stronger in response to
anger than fear stimuli.46 Second, we examined the dose-
dependency of these PD effects of OPN-OT. Last, we investigated
the relationship between nasal valve cross-sectional area and
evaluation of facial emotional expression along with impact of OT
on trust ratings of the same facial stimuli. To characterize
pharmacokinetics and evaluate potentially different relationships
between pharmacokinetics and PD by method of drug delivery,
we also explored the time course of blood plasma concentrations
of OT and physiologically interacting substances AVP49 and
cortisol,50 to index physiological stress via hypothalamus–pitui-
tary–adrenal axis activity.51 Modulation, or disproportionate
modulation, of social cognition (that is, of PD) after OPN-OT
administration, but not after IV OT producing comparable blood
exposure, would provide evidence that OPN-OT is, at least in part,
directly acting on the brain via upper posterior nasal pathways
rather than across the BBB.
MATERIALS AND METHODS
Participants
Participants were recruited among students at the University of Oslo
through advertisements. Eligible participants were males in good physical
and mental health between the ages of 18 to 35. Exclusion criteria
included use of any medications within the last 14 days, history of alcohol
or drug abuse, clinically relevant history of physical or psychiatric illness
and intelligence quotient o75.
A screening visit occurred between 3 and 21 days before randomization.
Trained graduate students administered the Wechsler Abbreviated Scale of
Intelligence52 and the Mini-International Neuropsychiatric Interview53 to
index intelligence quotient and conﬁrm the absence of psychiatric illness,
respectively. A physical examination was performed, including ECG and
the collection of routine blood samples. As per recommendations,15 an
otolaryngologist conﬁrmed normal nasal anatomy and patency in
participants and acoustic rhinometry data were collected (SRE 2000;
Rhinometrics, Lynge, Denmark). Nasal valve dimensions (that is, the
minimum cross-sectional area) and nasal cavity volume measures (TV0–5,
total volume from nostril to 5 cm deep; TV2–5, total volume from 2 to 5 cm
deep) were calculated from the acoustic rhinometry data.
Experimental design
A randomized, placebo-controlled, double-blind, double-dummy, four-
period crossover design was used. Participants were randomized to one of
four treatment sequences, using a four-period four-treatment Latin square
method (ACDB–BDCA–CBAD–DABC in a 4:4:4:4 ratio) with a period of at
least 6 days between treatments to prevent potential carryover and/or
practice effects. The study monitor (Smerud Medical Research Interna-
tional, Oslo, Norway) performed randomization and both the participants
and research team were masked to treatment using visually matching
intranasal devices and IV apparatus during data collection. A pragmatic
approach was taken for sample size determination reﬂecting the difﬁculty
of execution, complexity and burden on study subjects of the study. This
trial was approved by the Regional Committee for Medical and Health
Research Ethics (REC South East) and registered at http://clinicaltrials.gov
(NCT01983514). Participants provided written informed consent and were
reimbursed NOK 750 (approximately USD $125) per testing session.
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Breath Powered delivery device and OT administration
The Breath Powered, closed-palate, bi-directional nasal delivery device has
a mouthpiece connected in series to a delivery unit and a sealing
nosepiece optimized for nose-to-brain delivery (Supplementary Figure
S1).23,32 When the user slides the bespoke nosepiece into one nostril, it
forms a seal with the nostril opening and mechanically expands the narrow
slit-shaped part of the nasal valve. The intraoral pressure created by
blowing into the mouthpiece elevates the soft palate and creates an
airtight seal, which isolates the nasal cavity from the rest of the respiratory
system, thereby reducing drug loss from swallowing. The pressure of the
patient’s exhaled breath is released when the patient actuates the spray
pump, expanding the narrow nasal passages and propelling OT deeply
past the nasal valve for improved drug deposition on target regions,26 after
which the airﬂow balances pressure across the soft palate enabling the
exhaled breath to travel in the opposite direction and exit out the other
nostril.
The OT and placebo formulations were supplied by a cGMP
manufacturer (Sigma-Tau Industrie Farmaceutiche Riunite, Rome, Italy) to
a pharmaceutical service provider (Farma Holding, Oslo, Norway) for the
ﬁlling of the drug and placebo formulations into the OPN-OT devices.
The IV OT (10 IU/ml; Grindeks, Riga, Latvia) and placebo formulations (0.9%
sodium chloride) were added to a 0.9% sodium chloride solution for
infusion shortly before administration (600mL/h over 20min). The IV OT
dosage and infusion rate was guided by a pilot study (described in Section
1 and Supplementary Figure S2 of Supplementary Information), which
determined that that 1 IU delivered over 20min generates peripheral OT
concentrations equivalent to 24 IU delivered intranasally. All the partici-
pants self-administered an intranasal treatment using a Breath Powered
device and also received an IV solution—either OT or placebo depending
on randomization—in all treatment periods (solution ingredients and
administration regimen described in Section 2 of Supplementary
Information).
Experimental testing session procedure
At the beginning of each experimental session, exclusion and inclusion
criteria were conﬁrmed and the State–Trait Anxiety Inventory54 was
administered. Blood was sampled and acoustic rhinometry was performed
on all the participants.
Primary outcome parameters
Participants completed the social cognition task 40min after treatment in
a magnetic resonance imaging scanner while functional magnetic
resonance imaging and physiology data were recorded (results to be
reported separately). Participants were presented with visual stimuli
through magnetic resonance imaging-compatible goggles (VisualSystem;
NordicNeuroLab, Bergen, Norway) using E-Prime 2.0 (Psychology Software
Tools, PA, USA) and responded using a grip response collection system
(ResponseGrip, NordicNeuroLab).
For the primary emotional expression evaluation outcome measure,
participants were presented with 20 male and 20 female faces (as used
previously55) displaying angry, happy and emotionally ambiguous facial
expressions (derived from the Karolinska Directed Emotional Faces
database56) and 20 images of geometrical shapes (data not presented).
Following each presentation, participants were asked either: How angry is
this person? (anchors: not angry—very angry) or How happy is this person?
(anchors: not happy—very happy). Q2 was always the same: How much
would you trust this person? (anchors: not at all—very much). Participants
were asked to rank their answer on a visual analog scale from 1 to 5, with
location of the cursor on the visual analog scale randomized for each
question. Mean ratings for each of the questions were averaged
per session within each of the emotional categories, yielding seven
behavioral variables (Q1: Happy face—happy, Happy face—angry,
ambiguous face—happy, ambiguous face—angry, angry face—happy,
angry face—angry; Q2: Trust). These stimuli and questions were chosen to
assess three levels of emotion perception; ambiguous, non-ambiguous
with corresponding cues and ratings (for example, angry ratings of angry
faces) and non-ambiguous with conﬂicting cues and ratings (for example,
angry ratings of happy faces).
Pharmacokinetics
Blood samples were collected to assess peripheral levels of OT, AVP and
cortisol at baseline and ﬁve time points after the completion of the 20-min
IV administration (0, 10, 30, 60 and 120mins) throughout the session. Up to
two punctures with catheter placement were made to collect these blood
samples, which were centrifuged at 4 °C within 5min of blood draw with
plasma frozen at − 80 °C. Enzyme-linked immunosorbent assay using
commercial kits (Enzo Life Sciences, Farmingdale, NY, USA) was performed
using standard techniques (including sample extraction57).
Safety measures
At various points (−20, 0, 10, 30, 60 and 120mins relative to start of
functional magnetic resonance imaging) throughout testing, participants
reported the presence and severity of any adverse effects.
Statistical analysis
Analysis was conducted using IBM SPSS Statistics version 22 (IBM, Armonk,
NY, USA) to explore pharmacokinetics and examine the impact of
treatment on outcome measures. A linear mixed-model (LMM) approach
was adopted58 for the analysis of emotional expression evaluation,
pharmacokinetics, state anxiety and trustworthiness. In contrast to a
repeated-measures analysis of variance approach, LMM allows for the
inclusion of participants in the analysis even if data are missing for some of
the treatment conditions. All the models were ﬁtted using an unstructured
matrix. For any signiﬁcant main effects (that is, Po0.05), post hoc tests
were performed with the adjustment of critical P-values to correct for
multiple comparisons using a 5% false discovery rate.59 Experimental
treatment was both a ﬁxed and repeated effect in the LMM testing the
impact of treatment on emotion and trustworthiness ratings. To
investigate the impact of treatment on anxiety and blood plasma
concentration of OT, AVP and cortisol, an LMM was ﬁtted with three ﬁxed
factors (treatment, time, treatment × time) and one repeated factor
(treatment).
To investigate whether nasal environments changed between treatment
conditions, a repeated-measures multivariate analysis of variance was
performed with three dependent variables; minimum cross-sectional area,
TV0–5 and TV2–5. As nasal valve dimensions may differ according to an
individuals’ overall size and age, Pearson correlation coefﬁcients were also
calculated to assess the relationship between these factors at the time of
screening. The correlation between the posttreatment ratings of anger in
emotionally ambiguous faces and nasal valve dimensions was then
calculated. Bayes Factors using the Jeffreys–Zellner–Siow prior60 were
calculated for these correlations to assess the strength of evidence for the
null and alternative hypotheses. Conﬁdence intervals (CIs) for the
difference between correlations for each treatment condition were
calculated using Zou’s asymptotic method61 to compare the strength of
correlation to investigate whether the relationship between nasal valve
dimensions and anger ratings of ambiguous faces was signiﬁcantly greater
for some treatment conditions than others. As these variables are highly
related due to measurements being taken from the same individual,62 the
CIs were adjusted to account for overlap using the Fisher Z transformation.
RESULTS
Fifty-seven male volunteers were assessed for eligibility and 18
participants aged 20–30 years (M= 23.81, s.d. = 3.33) were
randomized (Supplementary Figure S3). Two participants with-
drew after enrollment (one withdrew after the ﬁrst session
(Placebo) and the other withdrew after completing three sessions
(8 IU OPN-OT, IV OT, placebo)). Data from these participants are
not included in the analyses.
Emotional expression evaluation
Table 1 and Figure 1 summarize the behavioral data. Due to
equipment difﬁculties, data were not collected during two (out of
64) testing sessions. An LMM revealed a signiﬁcant main effect of
treatment in the ratings of anger when presented with ambiguous
faces (F(3,14.72) = 7.62, P= 0.003; Figure 1a). Follow-up pairwise
comparisons (q= 0.05, revised critical value of Po0.017) indicated
that angry ratings for ambiguous faces were signiﬁcantly reduced
in the 8 IU OPN-OT treatment condition in comparison with both
the placebo (P= 0.011; mean decrease = 17%, SE decrease 6%) and
24 IU OPN-OT (P= 0.003; mean decrease = 17%, SE decrease 5%)
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treatments. There were no main effects of treatment observed for
other emotional categories or trustworthiness ratings collapsed
across emotional categories or for the anger or ambiguous faces.
There was a main effect of treatment in trustworthiness ratings of
the happy faces (F(3,14.67) = 3.32, P= 0.049) indicating different
ratings of trustworthiness depending on experimental treatment,
however, none of the follow-up pairwise comparisons survived
false discovery rate correction (q= 0.05, revised critical value of
Po0.008).
To explore the speciﬁcity of the effect for ambiguous faces
(vs non-ambiguous faces with corresponding cues and non-
ambiguous with conﬂicting cues) a percentage change score was
calculated comparing ratings after 8 IU OPN-OT and placebo
treatments, and comparing 8 IU OPN-OT with 24 IU OPN-OT
treatments (that is, the treatment comparisons that demonstrated
signiﬁcant differences in emotional ratings). Stimuli category was
both a ﬁxed and repeated effect in an LMM to assess the impact of
stimuli category on the reduction of anger ratings. For the LMM
comparing percentage change between the 8 IU OPN-OT and
placebo treatment, there was a main effect for stimuli type
(F(2,14.42) = 4.79, P= 0.025; Figure 2a). Follow-up pairwise
comparisons to the ambiguous stimuli category (q= 0.05, revised
critical value of Po0.025) indicated that the percentage reduction
of anger ratings of ambiguous stimuli was signiﬁcantly reduced
in comparison with the non-ambiguous/conﬂicting stimuli
(P= 0.012). For the LMM comparing percentage change between
the 8 IU OPN-OT and 24 IU OPN-OT treatment, there was a main
effect for stimuli type (F(2,14.05) = 7.01, P= 0.007; Figure 2b).
Follow-up pairwise comparisons to the ambiguous stimuli
category (q= 0.05, revised critical value of Po0.025) indicated
that the percentage reduction of anger ratings of ambiguous
stimuli was signiﬁcantly reduced in comparison with the non-
ambiguous/conﬂicting stimuli (P= 0.008).
Pharmacokinetic data
Out of 384 possible data points, 12 OT, 26 AVP and 18 cortisol
plasma concentration assessments were excluded due to techni-
cal issues relating to blood sample collection or analysis
(for example, difﬁculty drawing blood, too little blood volume
for analysis).
Oxytocin blood plasma concentration
The 4 (treatment) × 6 (time) LMM showed a signiﬁcant main
effect of treatment on OT blood plasma concentration
(F(3,90.34) = 12.42, Po0.001; Figure 3a), with pairwise comparisons
(q= 0.05, revised critical value of Po0.025) showing that plasma
OT concentration was signiﬁcantly increased in the IV (Po0.001),
8 IU OPN-OT (Po0.01) and 24 IU OPN-OT (Po0.001) treatments
compared with placebo. Importantly, none of the pairwise
comparisons between active treatment conditions reached
signiﬁcance. There was also a signiﬁcant main effect for time
(F(5,90.74) = 5.81, Po0.001), with follow-up pairwise analyses
(q= 0.05, revised critical value of Po0.017) indicating signiﬁcantly
increased plasma OT immediately after IV solution administration
in comparison with baseline (Po0.001) and all post-baseline time
points (10, 30, 60 and 120 min). There was also a signiﬁcant
condition × time interaction, F(15,90.5) = 2.67, P= 0.002. Follow-up
tests revealed a simple effect for time in the IV OT condition
(F(5,87.15) = 9.67, Po0.001), with signiﬁcantly higher concentra-
tions shortly after IV administration compared with all other time
points (all Po0.001). There was no effect of condition on OT
concentration just before (F(3,15.16) = 1.28, P= 0.32) or just after
(F(3,15.02) = 2.35, P= 0.1) the completion of the social cognition
task. An additional assessment of the main effect of condition on
the percentage change of OT concentration compared with
baseline at 30min (F(3,15.26) = 1.5, P= 0.25) and 60min
(F(3,15.04) = 0.63, P= 0.61) after treatment revealed no signiﬁcant
differences (Supplementary Figure S4).
Vasopressin blood plasma concentration
For the 4 (treatment) × 6 (time) LMM, there was a signiﬁcant
main effect of treatment on AVP blood plasma concentration
(F(3,82.42) = 4.55, P= 0.005; Figure 3b). Follow-up pairwise
comparisons (q= 0.05, revised critical value of Po0.0083) revealed
plasma AVP concentration was signiﬁcantly decreased after 24 IU
OPN-OT treatment in comparison with placebo (P= 0.008) and IV
OT (P= 0.013), and signiﬁcantly decreased after 8 IU OPN-OT
treatment in comparison with IV OT (P= 0.023). There was no
signiﬁcant main effect of time (F(5,90.63) = 1.81, P= 0.12) or
treatment × time interaction, F(15,82.46) = 1.03, P= 0.434.
Cortisol blood plasma concentration
For the 4 (treatment) × 6 (time) LMM, there was a signiﬁcant main
effect of treatment on cortisol blood plasma concentration
(F(3,84.77) = 4.82, P= 0.004; Supplementary Figure S5). Follow-up
pairwise comparisons (qo0.05, revised critical value of Po0.017)
revealed signiﬁcantly increased cortisol concentration following
1 IU IV OT treatment compared with placebo (P= 0.01) and 24 IU
OPN-OT (Po0.001), but not 8 IU OPN-OT. There was a signiﬁcant
main effect of time on cortisol blood plasma concentration
(F(5,90.07) = 2.4, P= 0.04), but no signiﬁcant follow-up pairwise
comparisons were found. Finally, there was no signiﬁcant
treatment × time interaction (F(15,84.72) = 0.421, P= 0.969).
Table 1. Participant ratings in the social cognition task
Outcomes 8 IU OPN-OT 24 IU OPN-OT IV OT Placebo Linear mixed-model main effect
df F P
Emotional expression evaluation
Angry ratings of ambiguous faces 2.11 (0.15) 2.46 (0.17) 2.32 (0.18) 2.41 (0.15) 3,14.72 7.62 0.003
Happy ratings of ambiguous faces 2.61 (0.14) 2.67 (0.12) 2.38 (0.14) 2.51 (0.13) 3,15.17 1.78 0.193
Angry ratings of angry faces 3.51 (0.2) 3.54 (0.16) 3.68 (0.2) 3.57 (0.16) 3,14.76 0.82 0.505
Happy ratings of angry faces 4.15 (0.62) 4.26 (0.57) 4.29 (0.54) 4.3 (0.36) 3,15 0.32 0.314
Angry ratings of happy faces 1.23 (0.02) 1.25 (0.02) 1.24 (0.02) 1.24 (0.02) 3,15 0.97 0.433
Happy ratings of happy faces 4.11 (0.16) 4.26 (0.14) 4.31 (0.13) 4.3 (0.09) 3,13.84 1.32 0.309
Trustworthiness 3.13 (0.04) 3.15 (0.05) 3.16 (0.05) 3.11 (0.03) 3,14.27 2.57 0.095
Abbreviations: IU, international unit; IV, intravenous; OPN-OT, OT delivered with the Breath Powered OptiNose device; OT, oxytocin. Unless speciﬁed otherwise,
values are estimated means based on linear mixed models with standard error in parenthesis.
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State anxiety and adverse events
For the 4 (treatment)×2 (time) LMM, there were no main effects of
treatment (F(3,30)=0.27, P=0.84) or time (F(1,30)=0.18, P=0.67) or
the treatment× time interaction on ratings of state anxiety (F(3,30)=
0.98, P=0.42). Adverse events (for example, brief dizziness) were
distributed across all four treatments (8 IU OPN-OT, three reports;
24 IU OPN-OT, two reports; IV OT, three reports; placebo, two reports).
Nasal valve dimensions
Repeated measures multivariate analysis of variance indicated no
main effect of treatment condition for nasal cavity dimensions
(F(9,104.8) = 0.41, P= 0.93). There was no relationship between age
(r= 0.06, 95% CI (−0.45, 0.54), n= 16, P= 0.84) and body mass index
(r=− 0.07, 95% CI (−0.55, 0.44), n= 15, P= 0.015) with nasal valve
dimensions at the time of screening.
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Figure 1. Mean emotional ratings by stimulus and treatment. Angry ratings of emotionally ambiguous faces were reduced after the
administration of 8 IU OPN-OT in comparison with placebo and 24 IU OPN-OT (a; FDR correction applied, q= 0.05, revised critical value of
Po0.017 for post hoc comparisons). There were no main effects for any of the other evaluation categories (b–f). Emotion ratings can
theoretically range from 1 to 5 and error bars represent standard error of the mean. *Po0.05. **Po0.01. FDR, false discovery rate; IU,
international unit; IV, intravenous; OPN-OT, OT delivered with the Breath Powered OptiNose device; OT, oxytocin.
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Analysis revealed a signiﬁcant relationship between nasal valve
dimensions (summed minimum cross-sectional area) and the
anger ratings of neutral faces after 8 IU OPN-OT treatment
(r=− 0.61, 95% CI (−0.85, − 0.14), n= 15, P= 0.015; Figure 4) with
a corresponding Bayes factor (B) of 3.62, representing substantial
evidence that these two variables are related.63 There was no
relationship between nasal valve dimensions and anger ratings of
ambiguous faces after 24 IU OT (r=− 0.14, 95% CI (−0.59, 0.38),
n= 16, P= 0.6; B= 0.22), IV OT (r= 0.11, 95% CI (−0.43, 0.59), n= 15,
P= 0.7; B= 0.21) or placebo (r= 0.04, 95% CI (−0.46, 0.53), n= 16,
P= 0.88; B= 0.19), with all respective Bayes factors providing
evidence that these variables were not related. A comparison of
the correlation coefﬁcients61 also revealed a signiﬁcant difference
between the correlations of the 8 IU and placebo, (r=− 0.65 (−1.1,
− 0.06)) and IV conditions (r=− 0.72 (−1.4, − 0.2)), but no
signiﬁcant difference in the correlation with 24 IU treatment
(r=− 0.42 (−0.97, 0.06)).
DISCUSSION
In this double-blind, placebo-controlled crossover trial in healthy
volunteers, we have demonstrated that 8 IU OPN-OT treatment
reduces the perception of anger in emotionally ambiguous facial
stimuli. Importantly, the current ﬁndings are the ﬁrst to suggest
that a low dose of OT is more effective than a higher dose in
modulating social cognition and that nasal valve dimensions
(summed minimum cross-sectional area) are associated with
treatment response in a treatment condition where brain effects
occur. Moreover, these results provide behavioral evidence that
OT delivered intranasally using a Breath Powered bi-directional
device reaches the brain and inﬂuences social cognition, whereas
IV administered OT, which similarly increased plasma OT
concentration, did not.
These data highlight the subtle effect of OT on the processing
of emotionally ambiguous facial stimuli in relation to anger
perception, as there was no difference in the ratings of angry or
happy faces. Although the speciﬁc effects of OT in response to
emotionally ambiguous stimuli indicate that OT only inﬂuences
the emotional assessment of stimuli which are non-abundant with
overt cues, the lack of effects in the happy and angry stimuli could
also be explained by the relatively low variability in the ratings of
these stimuli by healthy volunteers. There were also no differences
in ratings of trust for all facial stimuli between treatments,
however, there was a main effect for treatment on the ratings of
happy faces, reﬂecting differential ratings of trustworthiness of
happy faces between experimental treatments, although pairwise
comparisons did not reveal any signiﬁcant differences after false
discovery rate correction. Although the reported effects of OT
increasing in-group trustworthiness within economic paradigms
appear robust,6,8 observed effects on rating trustworthiness in
faces seem to be smaller.64 Perceived trustworthiness in faces may
produce smaller effects or not be as sensitive as other measures of
trust. The data also indicate that peripherally administered OT
increases blood cortisol concentrations compared with placebo
and intranasal OT. Although there was no signiﬁcant interaction
between treatment and time, this provides preliminary evidence
that peripherally administered OT may increase hypothalamus–
pituitary–adrenal axis activation but intranasally administered OT
has no such effects.
Converging biological and behavioral evidence suggests that
lower OT doses may be more efﬁcacious than higher doses. For
instance, compared with higher doses, lower doses increased
peripheral levels of OT in saliva,65 attenuated cortisol stress
responses66 and increased eye gaze in patients with Fragile X
syndrome.67 In animals, a low dose of OT administered shortly
after birth increased partner preference later in life, whereas
higher doses did not.68 Similarly, lower doses have been
associated with stronger increases in social recognition compared
with higher doses.69,70 The dose–response data reported here
provide useful preliminary evidence concerning the optimal dose
for social cognition modulation; however, extrapolation from
healthy individuals to patients must be with caution. Patients with
social-cognitive deﬁcits may respond differently than healthy
volunteers, so future studies should explore effects in patient
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Figure 2. Percentage reduction in anger ratings was greater when presented with ambiguous faces compared with non-ambiguous faces
(with corresponding or conﬂicting cues) after 8 IU OPN-OT compared with both placebo (a) and 24 IU OPN-OT (b) treatments (FDR correction
applied, q= 0.05, revised critical value of Po0.025 for post hoc comparisons). Ambiguous indicates anger ratings of ambiguous faces; NA-
corresponding indicates anger ratings of non-ambiguous faces with corresponding cues; NA-conﬂicting indicates anger ratings of non-
ambiguous faces with conﬂicting cues. Error bars represent s.e.m. *Po0.05. FDR, false discovery rate; IU, international unit; IV, intravenous;
OPN-OT, OT delivered with the Breath Powered OptiNose device; OT, oxytocin.
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populations to determine the generalizability of these ﬁndings to
target illnesses. Future work should also further investigate the
role of different delivery devices, administration routes, dosages
and social cognition tasks on the efﬁcacy of intranasal OT, ideally
using larger sample sizes given the limitation of a relatively small
sample size in the present study.
The nasal valve is the point of greatest resistance for airﬂow in
the nasal cavity. We show that participants with larger nasal valve
dimension rate ambiguous faces as less angry, suggesting that
nasal cavity anatomy has a role in determining the social-
behavioral response to intranasal OT administration. This role of
nasal anatomy emphasizes the importance of the method of nasal
delivery, and is consistent with the idea that deposition pattern
and nose-to-brain activity inﬂuence treatment effect. Despite the
increasing cost of psychiatric illness,71 the development of new
therapeutics has slowed dramatically.72,73 Although the develop-
ment of novel molecules is certainly important, innovation in the
method of intranasal administration may breathe new life into the
use of OT—which has already shown promise for the treatment of
psychiatric illness12,13—by increasing CNS activity, therapeutic
index and reliability of action by directing delivery more
effectively to upper posterior target areas and by addressing
barriers related to the nasal anatomy.
There are a number of interpretations regarding why no effect
was observed at the 24 IU OPN-OT dose, in contrast to the 8 IU
dose. For example, a higher OT dose is more likely to inﬂuence the
balance of AVP/OT, as evidenced by the decrease in AVP
concentration after 24 IU OPN-OT (but not 8 IU OPN-OT) observed
in the present study, which can modulate social behavior.49 Much
like OT, AVP receptors are located both centrally and
peripherally74,75 and have an important role in social behavior and
psychopathology.49 However, further investigation is required as
these results are in contrast with past research measuring AVP in
saliva after OT administration.76 Relatedly, observed levels of
plasma OT just after the completion of the social cognition task
were noticeably lower than past research,35,77,78 suggesting
targeted OT delivery using the Breath Powered device may
reduce systemic exposure while still producing central effects.79,80
It is worth noting, however, that the use of the Breath Powered
device in the current study renders direct comparison with these
past studies difﬁcult. Moreover, given the range of administration
techniques used in OT trials, and the high variability known to
exist in drug deposition patterns with nasal delivery devices, there
likely already exists a degree of variability in OT bioavailability
within and between studies.
A growing body of evidence suggests that OT modulates social
cognition in humans, particularly negatively valenced emotions.81
The present data are largely consistent with results from past
studies in that differences were only discovered on the perception
of anger in emotionally ambiguous faces. Prior studies suggest
that OT reduces bias towards negative information in anxious
individuals82–84 and decreases aversion to angry faces in healthy
adults,44 however, this is the ﬁrst study to the authors’ knowledge
to report data suggesting a reduction of perceived negativity in
healthy individuals. Such results have important implications for
disorders that are characterized by a negative bias towards social
stimuli (for example, social anxiety disorder).
In summary, our study presents new insights in relation to an
improved method of targeted intranasal OT delivery, and shows a
speciﬁc social-cognitive response after using the Breath Powered
device for delivery of OT compared with IV delivery producing
similar systemic exposure, suggesting that direct nose-to-brain
activity is being achieved. In addition, this study provides
preliminary evidence that a lower dose (8 IU) may offer greater
efﬁcacy than a higher dose (24 IU) when administered with the
Breath Powered device.
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Figure 3. Pharmacokinetics of plasma OT (a) and AVP (b) after the
administration of 8 IU OPN-OT, 24 IU OPN-OT, IV OT and placebo.
Error bars represent s.e.m. IU, international unit; IV, intravenous;
OPN-OT, OT delivered with the Breath Powered OptiNose device; OT,
oxytocin.
Figure 4. The relationship between angry ratings of ambiguous
faces after 8 IU OT treatment and bilaterally summed mean cross-
sectional areas in cm2 of the nasal valves with best-ﬁt line and 95%
conﬁdence band. The signiﬁcant inverse relationship indicates that
individuals with wider nasal valves rate ambiguous faces as less
angry after 8 IU OPN-OT administration.
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